Is Teva’s US Decline In Q3 Evidence Of A Broader Downward Trend?
Third Quarter Numbers Follow Sandoz’ View Of ‘Challenging Environment’
Executive Summary
Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.
You may also be interested in...
What’s Next? Five Things To Look Out For In November
In November, ANI Pharmaceuticals is hoping to complete a major acquisition, Viatris may shed further light on the state of the US generics industry and Generics Bulletin will host its eighth annual Global Generics & Biosimilars Awards, this year once again in person.
Sandoz Stung By The US Again As Sales And Margins Fall In Q3
As parent Novartis announced plans for a strategic review for its Sandoz business, the generics and biosimilars unit posted falling sales again for the third quarter of 2021, after championing stability in Q2. Sandoz is banking on biosimilars to return to growth.
Teva Likes Biosimilar Licensing Deals As It Cuts Full-Year Sales Guidance
Teva is keeping a keen eye out for opportunities like its US biosimilars agreement with Alvotech and more recent deal with Bioeq for biosimilar Lucentis as it attempts to maintain revenues in the coming years, following a cut to full-year sales guidance for 2021.